307538-20-1

Basic information

• Product Name: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
• Synonyms: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine
• CAS NO: 307538-20-1
• Molecular Weight: 334.603
• Mol File: 307538-20-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine(307538-20-1)
• EPA Substance Registry System: 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine(307538-20-1)

Safety Data

• Hazardous Substances Data: 307538-20-1(Hazardous Substances Data)

Upstream product

• 16313-66-9 5-bromoanthranilamide 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 38267-96-8 6-bromo-4-chloroquinozoline 
• 108-42-9 3-chloro-aniline 

Downstream Products

• 1041612-51-4 N-(3-chlorophenyl)-6-(4-(morpholinosulfonyl)phenyl)quinazolin-4-amine 

Relevant articles and documents

COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER

A combination comprising a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator. Methods for the prevention and treatment of a cancer comprises administering to a subject in need thereof, a therapeutically effective amount of a combination, the combination comprising: a compound of Formula (I) and/or Formula (Ia), or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator.

SMALL MOLECULE INHIBITORS OF EGFR AND PI3K

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.

Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5

A high-throughput cell-based screen identified a series of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of metabotropic glutamate receptor 5 (mGlu5). This Letter describes the SAR of this series and the profile of selected